Chronos Archive seal
The Human Record

Pablo Neruda

Case HR-ML051-TD · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
12 July 1904 – 23 September 1973
Synthetic DOB
1904-07-12
Index visit
1971-06-01 at age 66
Synthetic MRN
HR-ML051-SYN-TD

Teaching objective: De novo metastatic hormone-sensitive prostate cancer in a 66-year-old Chilean poet and diplomat posted abroad, on the NCCN prostate cancer guideline, the AUA/SUO advanced prostate cancer guideline and the CMID prostate cancer monograph. Urinary symptoms and bone pain with a hard prostate and a raised PSA lead to MRI, an MRI-targeted biopsy, conventional staging (CT and bone scan) and PSMA PET/CT; the disease is classified as low volume, and the choice is continuous androgen deprivation with apalutamide plus radiotherapy to the prostate, without docetaxel. The episode covers flare protection, early PSA response and the three-month PSA, germline and somatic testing, bone health (DXA, FRAX, vitamin D, calcium, exercise, a dental check and denosumab at the osteoporosis dose), the cardiometabolic risks of androgen deprivation, apalutamide's drug interaction with amlodipine, its rash and its effect on thyroid function, hot flashes, sexual health, fatigue, mood, and care in Spanish, his first language, around his writing and diplomatic work. His documented prostate cancer, operated on in France in July 1916 while he was ambassador, frames the episode; the dispute over his death two years later is history only.

Historical timeline

DateEventClaims
12 July 1904Born in Parral, Chile.CLM-0001
1920Begins publishing under the pen name Pablo Neruda.CLM-0002
1927Begins a series of consular posts in Asia and later in Buenos Aires, Barcelona and Madrid (to 1935).CLM-0003
1945Elected senator of the Republic.CLM-0003
28 December 1946A court judgment changes his birth name to Pablo Neruda.CLM-0002
21 January 1971The Senate approves his appointment as ambassador to France.CLM-0004
July 1971Health problems begin; operated on for prostate cancer in France.CLM-0005
21 October 1971Awarded the Nobel Prize in Literature.CLM-0006
November 1972Resigns as ambassador and returns to Chile.CLM-0004
23 September 1973Dies at the Clínica Santa María in Santiago, twelve days after the military coup; the death certificate gives cancer cachexia.CLM-0007, CLM-0008
8 November 2013Chile's medical legal service reports no relevant chemical substances in his exhumed remains.CLM-0009
October 2017An international forensic panel rejects cachexia as the cause of death without naming a cause.CLM-0010, CLM-0013
February 2023Clostridium botulinum DNA reported in a molar and bone; how it got there could not be determined.CLM-0011, CLM-0013
20 February 2024The Santiago appeals court orders the investigation reopened.CLM-0012

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Pablo Neruda was born on 12 July 1904 in the town of Parral in Chile. His father was a railway employee, and his mother, a teacher, died shortly after his birth; he spent his childhood and youth in Temuco.
Anchors the true birth date. His mother's cause of death is not recorded in the sources read.
confirmed Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports
Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
HISTMED Master Roster v3 supports
D He used the pen name Pablo Neruda from 1920. The Nobel Prize biography gives his real name as Neftalí Ricardo Reyes Basoalto; the Library of the National Congress of Chile gives his birth name as Ricardo Eliecer Neftalí Reyes Basoalto and records that a court judgment of 28 December 1946 changed it to Pablo Neruda.
Used for the display name and the alias. The two sources order the given names differently; the congressional biography's full form is used as the alias.
probable Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports
Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
D Between 1927 and 1935 he held a series of honorary consulships in Burma, Ceylon, Java, Singapore, Buenos Aires, Barcelona and Madrid; in 1945 he was elected a senator of the Republic and joined the Communist Party of Chile.
Anchors his long diplomatic and public life in the modern social history.
confirmed Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports
Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
D After the 1970 presidential election he was named Chile's ambassador to France; the Senate approved the appointment on 21 January 1971 and he presented his credentials at the end of that month. He resigned the post in 1972 and returned to Chile in November 1972.
Anchors his occupation and his residence in Paris at the index date (June 1971). The brief gave the posting as 1970 to 1972; the sources date the appointment to January 1971.
confirmed Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
Pablo Neruda (1904-1973). Memoria Chilena supports
D In July 1971 he began to have health problems and was operated on for prostate cancer; during his convalescence in France he wrote Geografía infructuosa. Later reports describe him as suffering from prostate cancer at the time of his death.
The documented anchor for prostate cancer in the modern episode. The congressional biography is the only source read that dates the diagnosis and the operation; the type of operation, the stage, the grade and any other treatment were not recorded in the sources read.
probable Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports
Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports
D The Nobel Prize in Literature was awarded to him on 21 October 1971, and he received it in Stockholm on 10 December 1971.
History after the modern episode's last visit.
confirmed Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
Pablo Neruda (1904-1973). Memoria Chilena supports
Pablo Neruda: Biographical. Nobel Prize in Literature 1971 supports
D He died on 23 September 1973 at the Clínica Santa María in Santiago, aged 69, twelve days after the military coup of 11 September 1973; he had been taken there by ambulance.
History after the modern episode.
confirmed Pablo Neruda (1904-1973). Memoria Chilena supports
Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports
Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias supports
D The official cause of death was cancer cachexia: wasting from his prostate cancer. The National Library of Chile's account says he died of prostate cancer.
Records what the death certificate stated; whether it was correct is disputed (CLM-0013).
confirmed Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports
Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports
Pablo Neruda (1904-1973). Memoria Chilena supports
D His remains were exhumed in 2013. In November 2013 the head of Chile's medical legal service said that no relevant chemical substances had been found that could be linked to his death, and that experts had found traces of medicine used to treat cancer.
History after his death; one part of the dispute over the cause of death.
confirmed Forensic tests show no poison in remains of Chilean poet Pablo Neruda (Associated Press) supports
Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports
D In October 2017 an international panel of 16 forensic experts said it was certain he had not died of cancer cachexia, as the death certificate stated; one member said there was no indication of cachexia and that he was obese at the time of death. The panel said it could neither exclude nor affirm a natural or violent cause of death, and reported potentially deadly bacteria in a sample from one of his molars.
History after his death; one part of the dispute over the cause of death. The panel's statement that he was not wasted at death is consistent with a man who was not cachectic; it is not used in the modern episode.
confirmed Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports
Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports
D In February 2023 laboratories in Canada and Denmark reported DNA of Clostridium botulinum in a molar and in bone fragments sampled in 2015. A member of the work said the finding was not definitive and did not tell what happened; panel members said they could not determine whether he had been poisoned or how the bacterium entered his body.
History after his death; the finding is consistent with poisoning but does not prove it, as the scientists said.
confirmed Pablo Neruda died with toxic bacteria in his body, say forensic experts. The Globe and Mail, February 15, 2023 supports
Was Neruda poisoned? Probe members say inconclusive (AFP) supports
D In February 2024 the Santiago appeals court unanimously ordered the investigation into his death reopened, after a judge had declined to do so in December 2023; the death certificate lists cancer.
History after his death. No later outcome was found in the sources read.
confirmed Death of Chilean poet Pablo Neruda should be reinvestigated, court rules (Associated Press) supports
R Whether he died of his prostate cancer, of another natural cause such as an infection, or of poisoning is disputed and unresolved. The death certificate gives cancer cachexia; the 2013 tests found no relevant chemical substances; the 2017 panel rejected cachexia without naming a cause; the 2023 finding of Clostridium botulinum could not show how it got there; and the investigation was reopened in 2024.
The record takes neither side. The cause of death is not used in the modern episode, which is set two years before his death and does not foreshadow it.
disputed Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 supports
Pablo Neruda did not die of cancer after all, experts say (Associated Press) supports
Forensic tests show no poison in remains of Chilean poet Pablo Neruda (Associated Press) disputes
Pablo Neruda died with toxic bacteria in his body, say forensic experts. The Globe and Mail, February 15, 2023 supports
Was Neruda poisoned? Probe members say inconclusive (AFP) supports
Death of Chilean poet Pablo Neruda should be reinvestigated, court rules (Associated Press) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed resolved confirmed active
S Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916 active confirmed both_with_link CLM-0005
S Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression active confirmed active CLM-0005
S Pelvic lymph node metastases: right external iliac and right obturator nodes active confirmed active CLM-0005
S Hormone-sensitive prostate cancer active confirmed active CLM-0005
S Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition active confirmed active CLM-0005
S Essential hypertension for five years, on amlodipine active confirmed active
S Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) active confirmed active
S Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) active confirmed active
S Prediabetes (hemoglobin A1c 5.9%) active confirmed active
S Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide resolved confirmed active
S Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit) active confirmed active
S Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observation active confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 1971-06-01 Prostate specific Ag [Mass/volume] in Serum or Plasma 46.8 ng/mL (high)
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 1971-06-01 Testosterone [Mass/volume] in Serum or Plasma 468 ng/dL
Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation
http://loinc.org · 2986-8
S 1971-06-01 Hemoglobin [Mass/volume] in Blood 13.6 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 1971-06-01 Leukocytes [#/volume] in Blood by Automated count 6.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1971-06-01 Platelets [#/volume] in Blood by Automated count 248 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 1971-06-01 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1971-06-01 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1971-06-01 Glucose [Mass/volume] in Serum or Plasma 104 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1971-06-01 Creatinine [Mass/volume] in Serum or Plasma 0.96 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 1971-06-01 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 87 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1971-06-01 Calcium [Mass/volume] in Serum or Plasma 9.6 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 1971-06-01 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 1971-06-01 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 1971-06-01 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 168 U/L (high)
Reference 40-129 U/L
http://loinc.org · 6768-6
S 1971-06-01 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 1971-06-01 Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma 208 U/L
Reference 135-225 U/L
http://loinc.org · 2532-0
S 1971-06-01 Hemoglobin A1c/Hemoglobin.total in Blood 5.9% (high)
Reference <=5.6%
http://loinc.org · 4548-4
S 1971-06-01 Cholesterol [Mass/volume] in Serum or Plasma 214 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 1971-06-01 Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 mg/dL
Reference >=40 mg/dL
http://loinc.org · 2085-9
S 1971-06-01 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 140 mg/dL (high)
Reference <=129 mg/dL
http://loinc.org · 13457-7
S 1971-06-01 Triglyceride [Mass/volume] in Serum or Plasma 140 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 1971-06-01 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 22 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 1971-06-01 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 http://loinc.org · 44261-6
S 1971-06-01 International Prostate Symptom Score [IPSS] 17 http://loinc.org · 80976-4
S 1971-06-01 Pain severity - 0-10 verbal numeric rating [Score] - Reported 6 http://loinc.org · 72514-3
S 1971-06-15 DXA Femur [T-score] Bone density -2.1 (low)
Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis
http://loinc.org · 38263-0
S 1971-06-15 DXA Lumbar spine [T-score] Bone density -1.4 (low)
Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis
http://loinc.org · 38267-1
S 1971-06-15 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 1971-06-15 Pain severity - 0-10 verbal numeric rating [Score] - Reported 5 http://loinc.org · 72514-3
S 1971-07-13 Prostate specific Ag [Mass/volume] in Serum or Plasma 6.2 ng/mL (high)
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 1971-07-13 Testosterone [Mass/volume] in Serum or Plasma 22 ng/dL (low)
Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation
http://loinc.org · 2986-8
S 1971-07-13 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1971-07-13 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1971-07-13 Glucose [Mass/volume] in Serum or Plasma 101 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1971-07-13 Creatinine [Mass/volume] in Serum or Plasma 0.98 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 1971-07-13 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 85 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1971-07-13 Calcium [Mass/volume] in Serum or Plasma 9.3 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 1971-07-13 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 25 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 1971-07-13 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 1971-07-13 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 141 U/L (high)
Reference 40-129 U/L
http://loinc.org · 6768-6
S 1971-07-13 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 1971-07-13 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 28 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 1971-07-13 Thyrotropin [Units/volume] in Serum or Plasma 2.4 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 1971-07-13 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 1971-07-13 International Prostate Symptom Score [IPSS] 14 http://loinc.org · 80976-4
S 1971-07-13 Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 http://loinc.org · 72514-3
S 1971-08-10 Leukocytes [#/volume] in Blood by Automated count 6.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1971-08-10 Eosinophils [#/volume] in Blood by Automated count 0.3 10*3/uL
Reference 0-0.5 10*3/uL
http://loinc.org · 711-2
S 1971-08-10 Creatinine [Mass/volume] in Serum or Plasma 0.97 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 1971-08-10 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 86 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1971-08-10 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 1971-08-10 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 1971-09-14 Prostate specific Ag [Mass/volume] in Serum or Plasma 0.18 ng/mL
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 1971-09-14 Testosterone [Mass/volume] in Serum or Plasma 14 ng/dL (low)
Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation
http://loinc.org · 2986-8
S 1971-09-14 Hemoglobin [Mass/volume] in Blood 12.9 g/dL (low)
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 1971-09-14 Leukocytes [#/volume] in Blood by Automated count 5.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1971-09-14 Platelets [#/volume] in Blood by Automated count 231 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 1971-09-14 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1971-09-14 Potassium [Moles/volume] in Serum or Plasma 4.5 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1971-09-14 Glucose [Mass/volume] in Serum or Plasma 102 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1971-09-14 Creatinine [Mass/volume] in Serum or Plasma 0.99 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 1971-09-14 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 83 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1971-09-14 Calcium [Mass/volume] in Serum or Plasma 9.2 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 1971-09-14 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 1971-09-14 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 1971-09-14 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 96 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 1971-09-14 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 1971-09-14 Thyrotropin [Units/volume] in Serum or Plasma 5.4 mIU/L (high)
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 1971-09-14 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 1971-09-14 Hemoglobin A1c/Hemoglobin.total in Blood 6.1% (high)
Reference <=5.6%
http://loinc.org · 4548-4
S 1971-09-14 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 1971-09-14 International Prostate Symptom Score [IPSS] 9 http://loinc.org · 80976-4
S 1971-09-14 Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 http://loinc.org · 72514-3
S 1971-10-05 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 1971-10-05 Total score [Mini-Cog] 5 http://loinc.org · 72233-0
S 1971-10-05 Total score [AUDIT-C] 2 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
1971-06-01Body height178 cm8302-2S
1971-06-01Body weight92.4 kg29463-7S
1971-06-01Body mass index (BMI) [Ratio]29.2 kg/m239156-5S
1971-06-01Systolic blood pressure146 mm[Hg]8480-6S
1971-06-01Diastolic blood pressure88 mm[Hg]8462-4S
1971-06-01Heart rate76 /min8867-4S
1971-06-01Respiratory rate14 /min9279-1S
1971-06-01Body temperature36.7 Cel8310-5S
1971-06-01Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1971-06-15Body height178 cm8302-2S
1971-06-15Body weight92 kg29463-7S
1971-06-15Body mass index (BMI) [Ratio]29 kg/m239156-5S
1971-06-15Systolic blood pressure142 mm[Hg]8480-6S
1971-06-15Diastolic blood pressure86 mm[Hg]8462-4S
1971-06-15Heart rate74 /min8867-4S
1971-06-15Respiratory rate14 /min9279-1S
1971-06-15Body temperature36.6 Cel8310-5S
1971-06-15Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1971-07-13Body height178 cm8302-2S
1971-07-13Body weight92.8 kg29463-7S
1971-07-13Body mass index (BMI) [Ratio]29.3 kg/m239156-5S
1971-07-13Systolic blood pressure152 mm[Hg]8480-6S
1971-07-13Diastolic blood pressure90 mm[Hg]8462-4S
1971-07-13Heart rate76 /min8867-4S
1971-07-13Respiratory rate14 /min9279-1S
1971-07-13Body temperature36.6 Cel8310-5S
1971-07-13Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1971-08-10Body height178 cm8302-2S
1971-08-10Body weight93 kg29463-7S
1971-08-10Body mass index (BMI) [Ratio]29.4 kg/m239156-5S
1971-08-10Systolic blood pressure136 mm[Hg]8480-6S
1971-08-10Diastolic blood pressure82 mm[Hg]8462-4S
1971-08-10Heart rate80 /min8867-4S
1971-08-10Respiratory rate14 /min9279-1S
1971-08-10Body temperature36.8 Cel8310-5S
1971-08-10Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1971-09-14Body height178 cm8302-2S
1971-09-14Body weight94.2 kg29463-7S
1971-09-14Body mass index (BMI) [Ratio]29.7 kg/m239156-5S
1971-09-14Systolic blood pressure132 mm[Hg]8480-6S
1971-09-14Diastolic blood pressure80 mm[Hg]8462-4S
1971-09-14Heart rate72 /min8867-4S
1971-09-14Respiratory rate14 /min9279-1S
1971-09-14Body temperature36.6 Cel8310-5S
1971-09-14Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1971-10-05Body height178 cm8302-2S
1971-10-05Body weight94.6 kg29463-7S
1971-10-05Body mass index (BMI) [Ratio]29.9 kg/m239156-5S
1971-10-05Systolic blood pressure128 mm[Hg]8480-6S
1971-10-05Diastolic blood pressure78 mm[Hg]8462-4S
1971-10-05Heart rate70 /min8867-4S
1971-10-05Respiratory rate14 /min9279-1S
1971-10-05Body temperature36.6 Cel8310-5S
1971-10-05Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Diagnosis, staging and a shared treatment decision within three weeks of the first visit1971-06-15completedBiopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake
Bone pain controlled, with a pain score of 2 or less and sleep restored1971-07-13completedPain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation
PSA of 0.2 ng/mL or less within about seven months of starting treatment1971-09-14completedPSA 46.8 to 0.18 ng/mL at three months
Blood pressure below 130/80 mm Hg on androgen deprivation1971-10-05completed152/90 at four weeks on apalutamide; 128/78 at the annual wellness visit on amlodipine 10 mg
Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk1971-10-05activeDenosumab given at four weeks after a dental check; vitamin D 28 ng/mL and rising; walking daily
Keep his morning writing and his official duties through treatment1971-10-05completedWriting every morning; one week of official engagements postponed during radiotherapy

Interventions

InterventionStatusGuideline
Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testingcompletedGL-NCCN-PROSTATE-2026, GL-AUA-APC-2026
Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CTcompletedGL-NCCN-PROSTATE-2026, GL-AUA-APC-2026, GL-CMID-2026
Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel controlcompletedGL-NCCN-PROSTATE-2026
Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official dutiescompletedGL-NCCN-PROSTATE-2026
Systemic therapy: apalutamide 240 mg daily from the consultation day and leuprolide 22.5 mg every twelve weeks from one week later, continuous; docetaxel not added for low-volume diseasecompletedGL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-TITAN-2019, GL-CHAARTED-2018
Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation, for low-volume metastatic diseasecompletedGL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-STAMPEDE-H-2018
Germline genetic testing with pre-test counseling, and somatic testing of the biopsy tissuecompletedGL-AUA-APC-2026, GL-NCCN-PROSTATE-2026
Bone health on androgen deprivation: DXA and FRAX, cholecalciferol 1945 units a day, calcium 1000 to 1200 mg a day from food, weight-bearing exercise, a dental examination, then denosumab 60 mg every six months for high fracture risk; DXA again in one to two yearscompletedGL-AUA-APC-2026, GL-CMID-2026, GL-CALGB90202-2014
Monitoring on androgen deprivation and apalutamide: PSA and testosterone every three months, blood count and chemistry, TSH every four months, blood pressure at every visit, hemoglobin A1c and lipids, rash, falls, hot flashes, sexual health, fatigue, mood and cognitioncompletedGL-CMID-2026, GL-ERLEADA-2026, GL-AUA-APC-2026
Apalutamide rash: triamcinolone 0.1% cream twice daily for two weeks, cetirizine 10 mg daily, fragrance-free emollient, continue apalutamide; stop it and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skincompletedGL-ERLEADA-2026, GL-NCCN-PROSTATE-2026
Atorvastatin 20 mg daily for primary prevention, with a lipid panel and ALT in six to twelve weekscompletedGL-USPSTF-STATIN-2022, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Pablo Neruda: Biographical. Nobel Prize in Literature 1971 Nobel Prize Outreach (NobelPrize.org) biography
SRC-0002 Reseña biográfica: Pablo Neruda. Reseñas biográficas parlamentarias Biblioteca del Congreso Nacional de Chile biography
SRC-0003 Pablo Neruda (1904-1973). Memoria Chilena Biblioteca Nacional de Chile biography
SRC-0004 Forensic tests show no poison in remains of Chilean poet Pablo Neruda (Associated Press) Global News other
SRC-0005 Pablo Neruda did not die of cancer after all, experts say (Associated Press) CBS News other
SRC-0006 Daley J. Pablo Neruda did not die of cancer, raising the possibility he was murdered. Smithsonian Magazine, October 25, 2017 Smithsonian Magazine other
SRC-0007 Pablo Neruda died with toxic bacteria in his body, say forensic experts. The Globe and Mail, February 15, 2023 The Globe and Mail other
SRC-0008 Was Neruda poisoned? Probe members say inconclusive (AFP) Hürriyet Daily News other
SRC-0009 Death of Chilean poet Pablo Neruda should be reinvestigated, court rules (Associated Press) VPM (NPR News) other
SRC-0011 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the low-volume classification on conventional imaging with a concordant PSMA PET/CT, apalutamide rather than abiraterone or enzalutamide, no docetaxel, radiotherapy to the prostate, apalutamide started one week before leuprolide for flare protection, denosumab at the osteoporosis dose rather than a bone agent for skeletal events, the amlodipine interaction, the grade 2 rash managed without stopping apalutamide, and the missed baseline TSH.
provenance reviewnot_startedSources: the Nobel Prize biography, the Library of the National Congress of Chile, the National Library of Chile (Memoria Chilena), and AP, AFP, CBS, Smithsonian, Globe and Mail and NPR reporting on the forensic investigations. The Fundación Pablo Neruda pages, the New York Times and The Guardian were not read. The posting to France is dated January 1971, not 1970.
safe messaging reviewnot_startedThe dispute over his death is recorded as R disputed, taking no side. No relative or other real person is named in the modern episode or given a statement, decision or health fact; relatives quoted in the news reports are not used. Mood screening is synthetic and below the thresholds for a safety assessment.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.